Ocular Oncology and Pathology

449 papers and 2.5k indexed citations i.

About

The 449 papers published in Ocular Oncology and Pathology in the last decades have received a total of 2.5k indexed citations. Papers published in Ocular Oncology and Pathology usually cover Ophthalmology (337 papers), Oncology (144 papers) and Molecular Biology (93 papers) specifically the topics of Ocular Oncology and Treatments (300 papers), Cutaneous Melanoma Detection and Management (74 papers) and Retinal Development and Disorders (56 papers). The most active scholars publishing in Ocular Oncology and Pathology are Arun D. Singh, Carol L. Shields, Bertil Damato, Jesse L. Berry and Jonathan W. Kim.

In The Last Decade

Fields of papers published in Ocular Oncology and Pathology

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Ocular Oncology and Pathology. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Ocular Oncology and Pathology

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Ocular Oncology and Pathology. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Ocular Oncology and Pathology with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025